Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S.

Published byLoreen Glenn Modified over 5 years ago

Similar presentations

Presentation on theme: "The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S."— Presentation transcript:

1 The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S. Andersson, Yago Nieto, Roy Jones, Marcos de Lima, Chitra Hosing, Uday Popat, Partow Kebriaei, Betul Oran, Amin Alousi, Katayoun Rezvani, Muzaffar Qazilbash, Qaiser Bashir, Catherine Bollard, Laurence Cooper, Laura Worth, Priti Tewari, Ian McNiece, Kaci Willhelm, Richard Champlin, Elizabeth J. Shpall  Clinical Lymphoma, Myeloma and Leukemia  Volume 14, Issue 1, Pages e1-e5 (February 2014) DOI: /j.clml Copyright © 2014 Elsevier Inc. Terms and Conditions

2 Figure 1 Kaplan-Meyer Estimates of Overall Survival (a) and Nonrelapse Mortality (b) for the Indicated Cohort. Symbols Indicate Censoring (Death or Progression) Abbreviations: Bu = busulfan; CBT = cord blood transplant; Clo = clofarabine; Flu = fludarabine; Mel = melphalan; NMR = nonrelapse mortality; OS, overall survival. Clinical Lymphoma, Myeloma and Leukemia  , e1-e5DOI: ( /j.clml ) Copyright © 2014 Elsevier Inc. Terms and Conditions

3 Figure 2 White Blood Cell Count per Microliters of Peripheral Blood Before and After Treatment/Stem Cell Infusion for Regimens 1 to 3. Average of at Least 5 Patients per Group + Standard Deviation is Shown Abbreviations: Bu = busulfan; CBT = cord blood transplant; Clo = clofarabine; CT = chemotherapy; Flu = fludarabine; Mel = melphalan; TBI = total body irradiation; Thio = thiotepa; WBC = white blood cell count. Clinical Lymphoma, Myeloma and Leukemia  , e1-e5DOI: ( /j.clml ) Copyright © 2014 Elsevier Inc. Terms and Conditions

Download ppt "The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S."

Similar presentations

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.

Haploidentical Transplantation with Post-transplant Cyclophosphamide and Melphalan-based Conditioning– A retrospective Analysis of the First 100 Patients.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma  Kyung Ah Yoh, Ho Sup Lee,

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma  Kyung Ah Yoh, Ho Sup Lee,
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.
Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S

Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
Clofarabine ± Fludarabine with Once Daily i. v

Clofarabine ± Fludarabine with Once Daily i. v
Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,

Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant  Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.

Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation by Takuya Sekine,

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation by Takuya Sekine,
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 

Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience 
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.

Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.
The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis  Nina.

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis  Nina.
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 

Similar presentations

Ads by Google